ghk-cu clinical trials safety efficacy Peptide Injection: Considerations – PlexusDx GHK-Cu vs AHK-Cu: Which Copper

Diabetes mellitus was defined as fasting plasma glucose concentration 126 mg/dL, or random/casual plasma glucose concentration 200 mg/dL, or Oral Glucose Tolerance Test 200 mg/dL, or HbA1c 6.5%, or taking antidiabetic medication, or ever been informed of a diagnosis of diabetes by a physician

FEBS Lett 457:2832 Crawley JN (1990) Coexistence of neuropeptides and classical neurotransmitters

The table below summarizes pivotal findings from apoptosis inhibition studies involving this compound

Zinc is most commonly included as part of an immunity-focused formulation but may be added to other infusions when clinically appropriate and assessed on an individual basis

Standard AOD-9604 Dosing Protocol Typical Dosing Range: Standard Dose: 250-500 mcg per day Clinical Trial Dose: 1 mg (1,000 mcg) per day (most effective in studies) Conservative Start: 250 mcg per day for first week Maintenance Range: 500 mcg per day for sustained protocols Frequency: Once daily, typically before breakfast Timing Rationale: Morning fasted state maximizes fat oxidation potential Cycle Length: 12-24 weeks for body composition protocols Administration Route: Subcutaneous injection (abdomen, thigh, or upper arm) Reconstitution: Bacteriostatic water, standard peptide protocols Note: Clinical trials used oral formulations, but subcutaneous administration is more common in current use due to improved bioavailability